Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma
Source : https://pubmed.ncbi.nlm.nih.gov/38935881/
This article endeavors to navigate the clinical journey of bispecific antibodies (BsAbs), from elucidating common toxicities and management strategies to examining novel agents and broadening access in community health care....
Integration of BsAbs into the repertoire of community-based cancer care represents a transformative step forward, promising to make advanced treatments more widely available. As we witness the expansion of these therapies from specialized academic centers to local practices, there is an accompanying imperative to refine toxicity management...
Protein arginine methyltransferase 2 controls inflammatory signaling in acute myeloid leukemia
Source : https://pubmed.ncbi.nlm.nih.gov/38902349/
Arginine methylation is catalyzed by protein arginine methyltransferases (PRMTs) and is involved in various cellular processes, including cancer development. PRMT2 expression is increased in several cancer types although its role...
Recent studies highlight the importance of a highly inflammatory BM microenvironment for AML risk stratification. The characterization of the BM immune microenvironment demonstrates distinct remodeling of the BM in response to AML-driven inflammation, highlighting specific B cell and T-cell populations that are expanded in ‘highly...
Spotlight on borderline-IGHV mutational status in chronic lymphocytic leukemia
Source : https://pubmed.ncbi.nlm.nih.gov/38903722/
Mutated or unmutated immunoglobulin heavy chain ( IGHV) gene is an important prognostic factor in chronic lymphocytic leukemia (CLL). However, a small fraction of patients with CLL are classified as...
Mutated or unmutated immunoglobulin heavy chain (IGHV) gene is an important prognostic factor in chronic lymphocytic leukemia (CLL). However, a small fraction of patients with CLL are classified as borderline (BL)-IGHV. Few data are available on this subgroup of CLL. In this paper, we retrospectively report and analyze data from 21 patients...
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study
Source : https://pubmed.ncbi.nlm.nih.gov/38683495/
Thrombocytopenia and neutropenia limited repeat dosing. Although limited clinical activity was detected, the dose-escalation phase was stopped early without establishing an MTD. The study was registered with ClinicalTrials.gov (NCT03106428).
Thrombocytopenia and neutropenia limited repeat dosing. Although limited clinical activity was detected, the dose-escalation phase was stopped early without establishing an MTD. The study was registered with ClinicalTrials.gov (NCT03106428).
Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11095866/
The primary objective of this randomized study was to determine whether a continuous dosing schedule (without the asparaginase-free interval) would result in less hypersensitivity reactions to PEGasparaginase (PEGasp) compared with...
A continuous dosing schedule of PEGasp is an effective approach to prevent antibody formation and inactivating hypersensitivity reactions. The continuous PEGasp schedule did not increase toxicity and did not affect the efficacy of the therapy.